Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
研究单位：[1]Merck Sharp & Dohme LLC[2]Anhui Provincial Hospital ( Site 0032)[3]The First Affiliated Hospital of Anhui Medical University ( Site 0005)[4]Wuhan Tongji Hospital ( Site 0021)
The purpose of this study is to determine the efficacy and safety of pembrolizumab or placebo given with best supportive care (BSC) in Asian participants with previously systemically treated advanced hepatocellular carcinoma (HCC). The primary hypothesis of this study is that overall survival is prolonged in participants who receive pembrolizumab compared to those who receive placebo.
